Intricon Corp.

Advanced engineering collaboration accelerates development of MyBreathPrint™, a revolutionary Class II medical device platform that detects lung cancer and other diseases from a single minute of breathing ST. PAUL, Minn. (Feb. 24, 2026) – Vocxi Health, a medical technology company developing the next generation of breath-based diagnostics, has partnered with Forj Medical to transform its MyBreathPrint™ device from a desktop prototype into a compact, handheld diagnostic platform designed for real-world use. The collaboration dramatically advanced the device’s performance and manufacturability, positioning it to revolutionize early disease detection through a simple, noninvasive breath test. MyBreathPrint™ uses graphene-based nano sensors and machine learning based algorithms to detect volatile organic compounds (VOCs) produced by the body in a person’s breath that correspond with specific diseases, including lung cancer, the world’s leading cause of cancer death. The device’s ultra-sensitive sensors can detect compounds at parts-per-billion concentration, a thousand times more sensitive than conventional medical gas sensors. Combined with AI/ML based algorithm, the system delivers accurate, near-instant results in seconds, potentially enabling widespread screening in clinics — and ultimately, in homes. Vocxi partnered with Forj Medical to translate its breakthrough science into a manufacturable, market-ready device. Forj Medical engineers employed design-for-manufacturability (DFM) principles and advanced miniaturization techniques to reduce the device’s size from that of a toaster to a handheld unit roughly the size of a deck of cards, without compromising precision or sensitivity. “Early detection is the key to saving lives, and the ability to identify cancer and other diseases from a simple breath test to increase compliance has been a long-standing goal in medicine,” said Ping Yeh, CEO of Vocxi. “Forj Medical’s engineering ingenuity allowed us to take our vision from a concept on the bench to a manufacturable device ready for clinical deployment. Together, we’ve created something that could make early cancer detection accessible to millions.” Forj Medical’s team solved multiple technical challenges in collaboration with Vocxi and its digital health partner S3 Connected Health. One of the most significant was maintaining clear electrical signals in concert with ultra-sensitive graphene sensors. The team identified and eliminated the noise sources through hardware design, custom algorithms, and more than 1,500 custom diagnostic tests conducted in rapid succession. The engineers also innovatively solved the challenge of humidity – a breakthrough in breath-detection devices. Forj Medical then built a foundation for scalable manufacturing. The team condensed hundreds of electronic components onto a single printed circuit board, developed automated testing and data analysis systems, and created packaging and labeling protocols for direct shipment to healthcare providers. “This collaboration exemplifies the early and close integration between the innovation and useability engineers in complex first-of-their-kind devices,” said Darren Gilmer, senior engineering manager, product development, at Forj Medical. “Vocxi’s sensor technology was exceptionally advanced, and our job was to make it manufacturable, reliable, and ready to scale. We achieved that by working side by side with Vocxi’s scientists to iterate, test, and refine every aspect of the original design.” The proximity of core team members in Minnesota’s Medical Alley facilitated rapid iteration and hands-on collaboration – literally delivering samples back and forth during testing and iteration – and gaining input from teams across the globe over a 24/7 timeline. Gilmer added a key process step was precise engineering that allowed software to “talk” to the hardware, which is particularly complex in devices that gather and decipher biometric data. Throughout the 18-month project, the partnership between Vocxi, Forj Medical, and S3 Connected Health resulted in three joint patents, a working prototype, and first production run of 500 units which performed well in clinical testing. The MyBreathPrint™ system’s compact form, cloud connectivity, and affordability make it a promising solution for large-scale cancer screening and early detection of multiple diseases, with potential to save countless lives and dramatically reduce healthcare costs. About Vocxi Health Vocxi Health is a medical technology company pioneering breath-based diagnostics to enable early, noninvasive detection of cancer and other serious diseases. Using proprietary nano sensor arrays and advanced machine learning algorithms, Vocxi’s MyBreathPrint™ device platform translates chemical patterns in human breath into actionable clinical data. The company’s mission is to make early detection accessible, accurate, and affordable for all. About Forj Medical Forj Medical is a vertically integrated contract design and manufacturing organization (CDMO) serving the medical technology industry. Formed through the merger of Intricon and Minnetronix Medical, Forj Medical offers end-to-end capabilities—from concept through commercial scale—in system design, microelectronics, precision molding, and advanced manufacturing. Headquartered in the heart of Medical Alley in St. Paul, Minn., with operations in Singapore, Indonesia, and Costa Rica, Forj Medical partners with device OEMs to accelerate innovation across key segments including diabetes care, advanced optics, surgical energy, vascular disease, drug delivery, and surgical navigation. For more information, please visit ForjMedical.com . # # #

ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- , a wholly-owned subsidiary of , announced on September 11, 2024, the acquisition of For more than four decades, Intricon Inc. has been a pioneer in the hearing health industry, specializing in the design, development, and manufacturing of advanced hearing solutions across the United States, Asia, and Europe. Their leadership in hybrid chip technology has established them as a key player in the global hearing device market, driving innovation and setting new standards in hearing health care. Through this acquisition, seeks to integrate advanced algorithms and technologies into the OTC hearing aid market. By harnessing expertise and global reach, aims to expand on legacy, driving further innovation to better serve the evolving needs of the industry. Shine Wang, CEO of Jinghao Medical, shared: We are excited to announce the acquisition of Intricon's hearing assets. With this strategic move, is furthering its vertical integration to enhance our expertise in firmware and algorithm development, creating even more advanced hearing aid technology. has made significant contributions to the hearing industry, and with the acquisition complete, will place an even stronger focus on advancing hearing technologies. Dr. XIONG Zhihui, CEO of , shared: "We are pleased to support the hearing market through our acquisition of Intricon's hearing assets. Our continued focus on advancing audiology algorithms, firmware, and hybrid hearing-aid chips, combined with Intricon's 47 years of proven expertise, positions to deliver even more innovative and high-quality hearing solutions to the industry." Media contact: inHearing Technology Inc Address: 2038 Ford Pkway 508, Saint Paul, MN 55116 Phone: +1 (651) 369-9360 Fax: +1 (651) 661-7719 SOURCE Huizhou Jinghao Medical Technology Co., Ltd

In a significant move aimed at becoming the world’s leading hearing aid company, Huizhou Jinghao Medical Technology Co., Ltd. has acquired Intricon’s Hearing Health business, assuming ownership and management of its hearing health assets starting September 11th, 2024. This acquisition strengthens Jinghao Medical’s global presence and lays a solid foundation for accelerating its expansion into international markets. By incorporating Intricon’s advanced algorithms, patented IP, and technology, Jinghao will further develop its product line and continue to push for technological advancements in hearing aids, hybrid chips, and global market growth. The acquisition reflects Jinghao Medical’s commitment to integrating Intricon’s 47 years of proven expertise in hearing aid technology, firmware, and algorithms. Jinghao will also introduce foreign talent and innovation to ensure that the legacy of Intricon continues to serve the market at a higher standard. This acquisition marks a pivotal moment in Jinghao’s globalization journey and its strategic focus on becoming a global leader in the hearing health industry. Huizhou Jinghao Medical Technology Co., Ltd. is China’s sole publicly listed hearing aid and hearing amplifier manufacturer. Renowned for providing high-quality, affordable hearing solutions, Jinghao serves both domestic and international markets with a broad range of hearing products, including behind-the-ear (BTE), in-the-ear (ITE), and bone conduction hearing aids. The company has built a solid reputation for innovation and affordability and is now poised to expand its market reach through this acquisition. Intricon is a global leader in the development and supply of advanced hearing aid technology, with 47 years of experience in designing and manufacturing miniature hearing aids, components, and systems. Intricon is known for its established relationships with top audiology manufacturers and emerging innovators. The company has a strong backend infrastructure with operations in Singapore and Indonesia, and it has played a critical role in next-generation hearing aid programs. This acquisition is a significant step towards Jinghao Medical’s long-term goal of becoming a global leader in the hearing aid industry. By integrating Intricon’s established technology, firmware, patented intellectual property, and algorithms, Jinghao gains a robust technological foundation that will enhance its global presence and product offerings. The addition of Intricon’s skilled team further strengthens Jinghao’s capabilities, bringing valuable expertise that will drive future innovation and ensure the company continues to deliver cutting-edge solutions to its customers. For Jinghao’s customers, this acquisition brings several advantages. By integrating Intricon’s product lines, Jinghao will offer a broader range of hearing health solutions that cater to the diverse needs of customers worldwide. Additionally, the combined resources and strengthened global infrastructure will lead to more efficient service and support, ensuring faster and more effective responses to customer needs. Over time, customers will benefit from enhanced product offerings, improved services, and potentially lower costs as a result of the integration and scaling efforts. Intricon’s Hearing Health business boasts several key strengths. With 47 years of proven innovation, the company has significantly influenced the hearing health industry through its patented intellectual property, firmware, and algorithms. Intricon has cultivated long-term relationships with leading original equipment manufacturers (OEMs) and emerging innovators, serving as a primary supplier to most of the “Big Five” audiology manufacturers. The company has also experienced continuous growth, actively participating in next-generation hearing aid programs and positioning itself to take advantage of the expanding over-the-counter (OTC) hearing health market. With global operations in Singapore and Indonesia, Intricon provides seamless service across multiple markets, and its strong industry reputation is underscored by an average customer tenure of over 20 years with its top five clients. With this acquisition, Jinghao Medical is poised to lead the global hearing health industry by delivering cutting-edge technology and customer-focused solutions. By integrating the strengths of both companies, Jinghao aims to drive further innovation in hearing health, making advanced, affordable hearing aids accessible to a larger market worldwide. Jinghao Medical welcomes new partnerships and collaborations in the hearing health sector. We sincerely invite healthcare professionals, distributors, and technology innovators to join us in our mission to improve hearing health solutions for millions of people globally!